Genomtec S.A.

Regulatory Filings • Aug 25, 2021

Patent application filed for the proprietary set of primers,diagnostic method, and the reaction mixture composition to geneticallydiagnose Salmonella enterica infections in LAMP technique.TheManagement Board of Genomtec S.A. (The "Issuer") informed today, i.e.,on August 25, 2021 that a patent application has been filed for thetechnology developed by the Issuer.The described applicationconcerns the proprietary set of primers, the diagnostic method, and thereaction mixture composition for the genetic diagnosis of Salmonellaenterica in the LAMP technique. The application was filed with thePolish Patent Office, Republic of Poland.Salmonellosis or foodpoisoning is one of the most common infectious diseases - both in humansand in animals. Animals and animal products are considered as the mainsource of Salmonella. All Salmonella infections begin with ingestionwith contaminated food or water and in humans can occur as acutegastroenteritis, enteric fever (typhoid fever or paradurium) orbacteremia. The most common cause of this infectious disease is due tobacteria belonging to the species Salmonella enterica.To date,culture-based tests are the most common microbiological methods fordiagnosing Salmonella enterica infections. However, despite their highsensitivity and specificity, they are labour- and time-consumingtechniques. Genetic tests offer rapid and relatively cheap method forthe identification of Salmonella. Due to low equipment requirements,isothermal method of genetic testing is an ideal diagnostic solutionboth for point-of-care testing (POCT), where the test can be performeddirectly in the patients' setting, as well as utilized for rapiddiagnostics in veterinary medicine and food industry.Thedeveloped set of primers is a key element of the diagnostic method basedon the LAMP technology utilized by the Issuer. Primers initiate theamplification reaction by recognizing a specific fragment of thepathogen's genome. The described patent application prevents the risk ofusing the same set of primers in an assay by competitors.TheIssuer's Management Board decided that filing the described patentapplication is a confidential information, as for an entity operating onthe molecular diagnostics market it is necessary to effectively protectintellectual property and designs. Properly secured intellectualproperty and designs may constitute the Issuer's competitive advantage,allowing safer commercialization under condition that full protection isensured on selected markets.In the opinion of the ManagementBoard, a high level of intellectual property protection will alsoprovide the Company with an advantageous negotiating position beforesigning any commercial contracts with selected partners as part of thecommercialization strategy implementation.Diagnosis of bacterialinfections is one of the key areas of technology developed by theIssuer. For these reasons, in the opinion of the Management Board, thisinformation meets the criteria of confidential information described inArt. 7 sec. 1 MAR.